利用多组学和人工智能:彻底改变肝细胞癌的预后和治疗方法
Zhen Wang1,2,3, Gangchen Zhou1,2, Rongchuan Cao2,4
1Department of Interventional Therapy, Zuanshiwan Campus, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
Frontiers in immunology
|August 7, 2025
概括
这项研究使用多omics数据确定了两种肝细胞癌 (HCC) 亚型. 由人工智能衍生的风险评分预测了预后,CEP55是肝癌的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 肝细胞癌 (HCC) 是一种流行性肝癌,死亡率和异质性高.
- 由于复杂的分子特征,针对HCC的个性化治疗策略具有挑战性.
- 多omics方法为HCC亚型和患者分层提供了洞察力.
研究的目的:
- 通过多组学方法识别HCC的不同分子亚型.
- 开发一种人工智能衍生风险评分 (AIDRS) 用于预测HCC患者的结果.
- 评估CEP55作为HCC的潜在治疗点.
主要方法:
- 来自HCC患者的综合多omics数据 (临床,转录基因,基因组,表观基因组).
- 采用了10个聚类算法来识别分子亚型.
- 利用生存分析,免疫分析,药物敏感性预测和机器学习用于AIDRS开发和CEP55评估.
主要成果:
- 确定了两个HCC亚型 (CS1和CS2),具有不同的临床结果和分子形状.
- CS2表现出更高的突变负担,免疫抑制和更差的预后.
- AIDRS准确地预测了患者的预后;高AIDRS与糟糕的结果和有限的免疫疗法反应相关.
- 在CS2中CEP55过度表达与较差的结果有关;CEP55敲击抑制了HCC进展在体外和体内.
结论:
- 多omics数据集成增强对HCC亚型,预后预测和个性化治疗的理解.
- AIDRS是HCC风险分层的一个强有力的工具.
- CEP55代表了HCC干预的有希望的治疗目标.
关键词:
CEP55 CEP55 的使用情况.人工智能衍生风险评分 (AIDRS)肝细胞癌 (HCC) 是一种肝细胞癌.免疫疗法 免疫疗法分子子类型 分子子类型多种主题的多种主题.索拉芬尼布 (Sorafenib) 是一个通过导管动脉化学栓塞 (TACE)更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.4K
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.0K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K